Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Provided By PR Newswire
Last update: Nov 5, 2025
– Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG –
– Zepzelca® and atezolizumab (Tecentriq®) combination approved as maintenance therapy in 1L ES-SCLC –
Read more at prnewswire.com
